A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC)

被引：0
|
作者：
Pili, R.
Haggman, M.
Stadler, W. M.
Gingrich, J. R.
Assikis, V. J.
Bjork, A.
Forsberg, G.
Carducci, M. A.
Armstrong, A. J.
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[2] Uppsala Univ, Uppsala, Sweden
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Peachtree Hematol Oncol, Atlanta, GA USA
[6] Act Biotech, Lund, Sweden
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4510
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer
    Wissing, Michel D.
    van Diest, Paul J.
    van der Wall, Elsken
    Gelderblom, Hans
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (05) : 635 - 661
  • [42] Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
    Dayyani, Farshid
    Gallick, Gary E.
    Logothetis, Christopher J.
    Corn, Paul G.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22): : 1665 - 1675
  • [43] Metastatic Castrate-Resistant Prostate Cancer Practical Review
    Moeller, Abby
    Cookson, Michael
    Patel, Sanjay G.
    PHYSICIAN ASSISTANT CLINICS, 2018, 3 (01) : 11 - +
  • [44] Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study
    Slovin, Susan F.
    Hamid, Omid
    Tejwani, Sheela
    Higano, Celestia S.
    Harzstark, Andrea
    Alumkal, Joshi J.
    Scher, Howard I.
    Chin, Kevin M.
    Gagnier, Paul
    McHenry, M. Brent
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [45] Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC).
    Sankhala, K. K.
    Chiorean, E. G.
    Armstrong, A. J.
    Borad, M. J.
    Traynor, A. M.
    Gadgeel, S. M.
    Langmuir, V. K.
    Eng, C.
    Kroll, S.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] METFORMIN IN CHEMOTHERAPY-NAIVE CASTRATION RESISTANT PROSTATE CANCER (CRPC): A MULTICENTER PHASE II TRIAL (SAKK 08/09)
    Rothermundt, C. A.
    Cathomas, R.
    Templeton, A.
    Winterhalder, R. C.
    Strebel, R.
    Baertschi, D.
    Pollak, M.
    Lui, L.
    Crowe, S.
    Gillessen, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 302 - 302
  • [47] The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).
    Horvath, Lisa
    Chatfield, Mark D.
    Lee-Ng, Michelle
    Lin, Hui-Ming
    Castillo, Lesley
    Breit, Samuel N.
    Brown, David A.
    Molloy, Mark P.
    Marx, Gavin M.
    Pavlakis, Nick
    Boyer, Michael J.
    Stockier, Martin R.
    Wykes, Richard
    Henshall, Susan M.
    Mahon, Kate Lynette
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed
    Halabi, Susan
    Lin, Chen-Yen
    Small, Eric Jay
    Armstrong, Andrew J.
    Kaplan, Ellen B.
    Petrylak, Daniel Peter
    Sternberg, Cora N.
    Shen, Liji
    Oudard, Stephane
    De Bono, Johann Sebastian
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [49] Phase I trial of a targeted therapy with a psa-based vaccine and ipilimumab in patients (pts) with metastatic castrate-resistant prostate cancer (CRPC)
    Gulley, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 24 - 24
  • [50] A Phase I vaccine study with metastatic tumour as the antigen source in patients with advanced castrate-resistant prostate cancer
    Gardiner, R. A.
    Schmidt, C.
    Ellem, K. A. O.
    Lopez, A.
    Scells, B.
    O'Connor, L.
    Nicol, D. L.
    McClintock, P.
    Yaxley, J.
    BJU INTERNATIONAL, 2009, 103 : 12 - 13
12345